ReproCELL Acquires Stem Cell Companies

ReproCELL listed on Japan’s JASDAQ Growth Market last July. The company’s sales for the year ending March 31 grew 9.7% to ¥460 million ($4.5 million = ¥100.25 = $1), with its IPS Cell and Diagnostic Service businesses accounting for 88% and 22% of revenues, respectively. Research products include iPSC-derived hepatocytes and cardiomyocytes.

Tokyo, Japan 8/4/14; Sedgefield, UK 8/5/14—Publicly held Japanese firm ReproCELL, a supplier of iPSC-derived products, and media and reagents for cell culture, has acquired UK-based Reinnervate and US-based BioServe Biotechnologies for an undisclosed amount. Reinnervate provides 3-D cell-culture products. BioServe supplies human tissue and other biological samples. “The ReproCELL group of companies now offers products and services that span the 2-D and 3-D cell culture, stem-cell culture media, iPSC-derived cells and human-tissue samples,” said ReproCELL CEO Chika Yokoyama. “Our customers can now move easily from testing monolayer culture to 3-D culture to human-tissue systems all with support from a single source.”

< | >